Ana Gorostidi1,2, José Félix Martí-Massó3,4,5,6,7, Alberto Bergareche3,4,5,6, Mari Cruz Rodríguez-Oroz3,5,6,8, Adolfo López de Munain3,4,5,6,7, Javier Ruiz-Martínez3,4,5,6. 1. Genomics Platform, Biodonostia Research Institute, Dr. Begiristain s/n, San Sebastian, 20014, Gipuzkoa, Spain. ana.gorostidi@biodonostia.org. 2. Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain. ana.gorostidi@biodonostia.org. 3. Neurology Service, Hospital Universitario Donostia, San Sebastian, Spain. 4. Ilundain Fundazioa, San Sebastian, Spain. 5. Neuroscience Area, Biodonostia Research Institute, San Sebastian, Spain. 6. Centro de Investigación Biomédicas en Red Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain. 7. Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Spain. 8. Ikerbasque. Basque Foundation for Science, Bilbao, Spain.
Abstract
BACKGROUND: Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting millions of people. Genome-wide association studies (GWAS) have found >25 genetic risk factors and at least 15 loci directly associated with PD. Recent advances in new next-generation DNA sequencing technologies, such as the semiconductor-based Ion Torrent platform, make multigene sequencing cheaper, faster, and more reliable. OBJECTIVES: Our objective was to test the power of this next-generation sequencing technology to analyze large samples by screening the majority of the most relevant PD-related genes known for single and compound mutations. METHODS: To archive a rapid, robust, and cost-effective genetic analysis of a PD cohort, we designed a multiplex, polymerase chain reaction (PCR)-based primer panel to amplify and sequence coding exons of 15 PD-associated genes (SNCA, LRRK2, PARK2, PINK1, PARK7, GIGYF2, ATP13A2, UCHL1, PLA2G6, FBXO7, EIF4G1, VPS35, ACMSD, APOE, and GBA). We conducted parallel sequencing using the Ion Torrent Personal Genome Machine(®) system to detect mutations in 92 blood DNA samples from PD patients. RESULTS: After bioinformatics analysis and filtering, 95.13 % coverage of the targeted region was obtained at >40-fold mean coverage. The results revealed 44 previously documented variants in these 15 genes, with five revealed as pathogenic. We also discovered six novel variants, five of which had an in silico prediction of being pathogenic. CONCLUSIONS: Benchtop next-generation sequencing is a powerful method for genetic screening for PD. Our results indicated that it yielded a high frequency of discovery (66 %; n = 92) of variants in carriers from an enriched Spanish PD sample.
BACKGROUND:Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting millions of people. Genome-wide association studies (GWAS) have found >25 genetic risk factors and at least 15 loci directly associated with PD. Recent advances in new next-generation DNA sequencing technologies, such as the semiconductor-based Ion Torrent platform, make multigene sequencing cheaper, faster, and more reliable. OBJECTIVES: Our objective was to test the power of this next-generation sequencing technology to analyze large samples by screening the majority of the most relevant PD-related genes known for single and compound mutations. METHODS: To archive a rapid, robust, and cost-effective genetic analysis of a PD cohort, we designed a multiplex, polymerase chain reaction (PCR)-based primer panel to amplify and sequence coding exons of 15 PD-associated genes (SNCA, LRRK2, PARK2, PINK1, PARK7, GIGYF2, ATP13A2, UCHL1, PLA2G6, FBXO7, EIF4G1, VPS35, ACMSD, APOE, and GBA). We conducted parallel sequencing using the Ion Torrent Personal Genome Machine(®) system to detect mutations in 92 blood DNA samples from PDpatients. RESULTS: After bioinformatics analysis and filtering, 95.13 % coverage of the targeted region was obtained at >40-fold mean coverage. The results revealed 44 previously documented variants in these 15 genes, with five revealed as pathogenic. We also discovered six novel variants, five of which had an in silico prediction of being pathogenic. CONCLUSIONS: Benchtop next-generation sequencing is a powerful method for genetic screening for PD. Our results indicated that it yielded a high frequency of discovery (66 %; n = 92) of variants in carriers from an enriched Spanish PD sample.
Authors: Alexander Zimprich; Bertram Müller-Myhsok; Matthew Farrer; Petra Leitner; Manu Sharma; Mary Hulihan; Paul Lockhart; Audrey Strongosky; Jennifer Kachergus; Donald B Calne; Jon Stoessl; Ryan J Uitti; Ronald F Pfeiffer; Claudia Trenkwalder; Nikolaus Homann; Erwin Ott; Karoline Wenzel; Friedrich Asmus; John Hardy; Zbigniew Wszolek; Thomas Gasser Journal: Am J Hum Genet Date: 2003-12-19 Impact factor: 11.025
Authors: Demetrius M Maraganore; Mariza de Andrade; Alexis Elbaz; Matthew J Farrer; John P Ioannidis; Rejko Krüger; Walter A Rocca; Nicole K Schneider; Timothy G Lesnick; Sarah J Lincoln; Mary M Hulihan; Jan O Aasly; Tetsuo Ashizawa; Marie-Christine Chartier-Harlin; Harvey Checkoway; Carlo Ferrarese; Georgios Hadjigeorgiou; Nobutaka Hattori; Hideshi Kawakami; Jean-Charles Lambert; Timothy Lynch; George D Mellick; Spiridon Papapetropoulos; Abbas Parsian; Aldo Quattrone; Olaf Riess; Eng-King Tan; Christine Van Broeckhoven Journal: JAMA Date: 2006-08-09 Impact factor: 56.272
Authors: Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan B Bressman; William K Scott; Caroline Tanner; Susan Mickel; Howard Andrews; Cheryl Waters; Stanley Fahn; Lucien Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Karen Marder; Lorraine N Clark Journal: Arch Neurol Date: 2010-09
Authors: William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood Journal: Lancet Date: 2005 Jan 29-Feb 4 Impact factor: 79.321
Authors: Ken Y Hui; Heriberto Fernandez-Hernandez; Jianzhong Hu; Adam Schaffner; Nathan Pankratz; Nai-Yun Hsu; Ling-Shiang Chuang; Shai Carmi; Nicole Villaverde; Xianting Li; Manual Rivas; Adam P Levine; Xiuliang Bao; Philippe R Labrias; Talin Haritunians; Darren Ruane; Kyle Gettler; Ernie Chen; Dalin Li; Elena R Schiff; Nikolas Pontikos; Nir Barzilai; Steven R Brant; Susan Bressman; Adam S Cheifetz; Lorraine N Clark; Mark J Daly; Robert J Desnick; Richard H Duerr; Seymour Katz; Todd Lencz; Richard H Myers; Harry Ostrer; Laurie Ozelius; Haydeh Payami; Yakov Peter; John D Rioux; Anthony W Segal; William K Scott; Mark S Silverberg; Jeffery M Vance; Iban Ubarretxena-Belandia; Tatiana Foroud; Gil Atzmon; Itsik Pe'er; Yiannis Ioannou; Dermot P B McGovern; Zhenyu Yue; Eric E Schadt; Judy H Cho; Inga Peter Journal: Sci Transl Med Date: 2018-01-10 Impact factor: 17.956
Authors: Oluwafemi G Oluwole; Helena Kuivaniemi; Shameemah Abrahams; William L Haylett; Alvera A Vorster; Carel J van Heerden; Colin P Kenyon; David L Tabb; Michael B Fawale; Taofiki A Sunmonu; Abiodun Ajose; Matthew O Olaogun; Anastasia C Rossouw; Ludo S van Hillegondsberg; Jonathan Carr; Owen A Ross; Morenikeji A Komolafe; Gerard Tromp; Soraya Bardien Journal: BMC Med Genet Date: 2020-02-04 Impact factor: 2.103
Authors: Marina V Shulskaya; Anelya Kh Alieva; Ivan N Vlasov; Vladimir V Zyrin; Ekaterina Yu Fedotova; Natalia Yu Abramycheva; Tatiana S Usenko; Andrei F Yakimovsky; Anton K Emelyanov; Sofya N Pchelina; Sergei N Illarioshkin; Petr A Slominsky; Maria I Shadrina Journal: Front Aging Neurosci Date: 2018-05-15 Impact factor: 5.750